Home / Market News / $CVS
benzinga Corporate Catalyst Impact 85/100 ● negative

CVS Health shares are trading lower after the CMS 2027 Medicare Advantage Part D Release gave the company's Silverscript Insurance contract, a large Medicare PDP contract, a 2.5-star rating. A lower rating could turn people toward competing plans, which can hurt downstream prescription volume at its retail business.

Oct 8, 2026, 10:01 PM UTC · Primary ticker $CVS

CVS Health shares are down significantly due to a low Medicare Part D rating for its Silverscript plan. This downgrade could lead to member attrition, directly impacting CVS's insurance segment and indirectly reducing prescription volume at its retail pharmacies. The news highlights regulatory risk and competitive pressures within the highly lucrative Medicare Advantage market.

The 2.5-star rating for CVS's Silverscript Medicare Part D plan is a significant negative catalyst. Medicare Advantage plans with lower ratings often experience reduced enrollment as beneficiaries are incentivized to choose higher-rated plans. This directly impacts CVS's Aetna insurance segment through lower premiums and indirectly hurts its retail pharmacy business by reducing prescription fill volumes from departing members. The healthcare sector, particularly managed care organizations and pharmacy benefit managers, is highly sensitive to CMS ratings and regulatory changes. This event underscores the competitive intensity in the Medicare market and could lead to a re-evaluation of CVS's growth trajectory and profitability, potentially creating trading opportunities for competitors like Humana and UnitedHealth Group.

$CVS negative Direct impact from Medicare Part D rating downgrade and potential member loss.
$HUM positive Potential beneficiary gains from CVS's lower rating.
$UNH positive Potential beneficiary gains from CVS's lower rating.
$WBA neutral Indirect competitive pressure in retail pharmacy, but not directly impacted by the insurance rating.
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.